This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.

Skip to main content

United Kingdom | EN-GB

Recent Searches
Quick Links
Capabilities People Insights News

Cortex - Life Sciences Insights

Kate Burgess

Associate, DLA Piper

Leeds, United Kingdom

kate.burgess@dlapiper.com

About me

Kate is an associate at DLA Piper with experience of advising on, negotiating and drafting large-scale outsourcing, technology and commercial contracts, particularly in the context of the life sciences sector.

Clinical Trial Regulations in the EU – how will the UK follow?

Feb 18, 2022

Clinical Trial Regulations in the EU – how will the UK follow?

By Kate Burgess

The European Medicines Agency has confirmed that the new Clinical Trials Regulation is now in effect as of 31 January 2022. Please see...

Do medical devices have systematic bias?

Dec 13, 2021

Do medical devices have systematic bias?

By Kate Burgess Anna Ward

An investigation has been launched by the UK’s Department of Health and Social Care (“DHSC”) with the overall aim of improving healthcare...

The future regulation of medical devices in the UK under the Medicines and Medical Devices Act 2021

Mar 22, 2021

The future regulation of medical devices in the UK under the Medicines and Medical Devices Act 2021

By Kate Burgess Anna Ward

The Medicines and Medical Devices Act 2021 (the “MMD Act”) was granted royal assent on 11th February 2021. The MMD Act confers broad...

EUDAMED: streamlining the registration process between Legacy and Regulation Devices

Feb 22, 2021

EUDAMED: streamlining the registration process between Legacy and Regulation Devices

By Kate Burgess

The European Commission has published a guidance document aiming to further assist manufacturers with understanding how Legacy Devices...

An ever-changing landscape - European regulator looks to speed up authorisation process for modified vaccines addressing COVID-19 variants

Feb 16, 2021

An ever-changing landscape - European regulator looks to speed up authorisation process for modified vaccines addressing COVID-19 variants

By Kate Burgess

At a time where drug makers are taking action to develop modified versions of their vaccines in order to address the evolving variants of...

DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.

© 2023 DLA Piper